6Cooksley WG,Piratvisuth T,Lee SD,et al.Peginterferon alpha-2a (40 kDa):an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.J Viral Hepat,2003,10:298-305.
7Lau GK,Piratvisuth T,Luo KX,et al.Peginterferon Alfa-2a,lamivudine,and the combination for HBeAg-positive chronic hepatitis B.N Engl J Med,2005,352:2682-2695.
8Marcellin P,Lau GK,Bonino F,et al.Peginterferon alfa-2a alone,lamivudine alone,and the two in combination in patients with HBeAg-negative chronic hepatitis B.N Engl J Med,2004,351:1206-1217.
9Janssen HL,van Zonneveld M,Senturk H,et al.Pegylated interferon alfa-2b alone or in combination with lamivudinefor HBeAg-positive chronic hepatitis B:a randomised trial.Lancet,2005,365:123-129.
10Lau GKK,Piratvisuth T,Luo KX,et al.Durability of response and occurrence of late response to peginterferon alpha-2a (40KD)[PEGASYS] one year post-treatment in patients with HBeAg-positive chronic hepatitis B.J Hepatology,2006,44(Suppl 2),S23-24.
1Micco L, Peppa D, Loggi E, et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol, 2013,58:225-233.
2Chen J, Wang Y, Wu X J, et al. Pegylatcd interferon a-2b up- regulates specific CD8 + T cells in patients with chronic hepatitis B. World J Gastroenterol, 2010,16 :6145.
3Gheorghitfi VI, Cfiruntu FA, Curescu M, et al. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study. J Gastrointestin Liver Dis, 2013,22 :27- 32.
4Rijckhorst V, Hansen BE, Ferenci P, et al. Validation of a Stopping rule at week 12 using HBsAg and HBV DNA for HBeAg- negative patients treated with peginterferon alfa-2a. J Hepatol, 2012,56 : 1006-1011.
